# Masafumi Ikeda

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/masafumi-ikeda/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,530 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 80 |
| i10-index | 310 |
| Last Known Institution | National Cancer Center Hospital East |
| OpenAlex ID | https://openalex.org/A5022537134 |
| ORCID iD | https://orcid.org/0000-0002-4050-2086 |
| Works | 1,019 |

## Researcher papers

- [Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study](https://scholariq.org/papers/randomized-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-or-gemcitabine/)
- [Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study](https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies](https://scholariq.org/papers/clinical-utility-of-circulating-tumor-dna-sequencing-in-advanced/)
- [Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial](https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/)
- [Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study](https://scholariq.org/papers/nivolumab-alone-or-in-combination-with-cisplatin-plus-gemcitabine-in-japanese/)
- [Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-s-1-compared-with-observation-in-resected-biliary-tract-cancer-jcog1202/)
- [Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO](https://scholariq.org/papers/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-2/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [National Cancer Center Hospital East](https://scholariq.org/institutions/national-cancer-center-hospital-east/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.